CA VSV
Alternative Names: CA-VSVLatest Information Update: 28 Aug 2023
At a glance
- Originator University of California, San Diego
- Developer Cytonus Therapeutics; University of California, San Diego
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Haematological malignancies
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 19 Jul 2019 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to July 2019 (Cytonus Therapeutics pipeline, July 2019)